Comparison of opioid prescribing upon hospital discharge in patients receiving tapentadol versus oxycodone following orthopaedic surgery
- PMID: 34089144
- DOI: 10.1007/s11096-021-01290-7
Comparison of opioid prescribing upon hospital discharge in patients receiving tapentadol versus oxycodone following orthopaedic surgery
Abstract
Background The changing of opioids during the transition of care from hospital to home may be associated with harm. Objective To compare patients receiving tapentadol IR versus oxycodone IR following orthopaedic surgery during hospitalisation with regard to the changing of opioids at hospital discharge. Setting A major metropolitan tertiary referral hospital in Australia. Methods This is a retrospective cohort study. Participants included adult orthopaedic surgery patients receiving postoperative tapentadol IR or oxycodone IR during hospitalisation between 1 January 2018 and 30 June 2019. Main outcome measure The proportion of patients for whom the opioid prescribed was changed at hospital discharge. Results The study cohort included 199 patients. Of these, 100 patients received oxycodone and 99 patients received tapentadol post-operatively during hospitalisation. The mean age was 66 years (SD, 12 years) and 111 (56%) were female. The most common surgeries were total knee arthroplasty (91, 46%), total hip arthroplasty (63, 32%) and shoulder surgery (26, 13%). Patients in the tapentadol group were more likely to be changed to a different opioid upon hospital discharge than the oxycodone group (57% versus 9%, difference 48% [95% CI 36-59%, p < 0.01). After adjusting for confounders, post-operative tapentadol use was more likely to be associated with opioid changing upon discharge (OR 16.5, 95% CI 6.7 to 40.8, p < 0.01). Conclusions The post-operative use of tapentadol IR during hospitalisation was associated with an increased likelihood of opioid changing at hospital discharge. This practice could have patient safety implications.
Keywords: Opioid; Orthopaedic procedures; Postoperative pain; Prescribing pattern; Tapentadol.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Gastrointestinal Adverse Events in Hospitalized Patients Following Orthopedic Surgery: Tapentadol Immediate Release Versus Oxycodone Immediate Release.Pain Physician. 2021 May;24(3):E309-E315. Pain Physician. 2021. PMID: 33988952
-
Effect of discharge opioid on persistent postoperative opioid use: a retrospective cohort study comparing tapentadol with oxycodone.Anaesthesia. 2023 Apr;78(4):420-431. doi: 10.1111/anae.15933. Epub 2022 Dec 19. Anaesthesia. 2023. PMID: 36535726
-
Cost-effectiveness of tapentadol immediate release versus oxycodone immediate release for acute post-operative pain after major hip surgeries.Curr Med Res Opin. 2022 Jan;38(1):115-121. doi: 10.1080/03007995.2021.1993161. Epub 2021 Oct 23. Curr Med Res Opin. 2022. PMID: 34641744
-
[Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies].Schmerz. 2012 Feb;26(1):16-26. doi: 10.1007/s00482-011-1132-2. Schmerz. 2012. PMID: 22366930 German.
-
Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.Drugs. 2010 Sep 10;70(13):1719-43. doi: 10.2165/11204470-000000000-00000. Drugs. 2010. PMID: 20731478 Review.
Cited by
-
Effect of different low doses of intrathecal morphine (0.1 and 0.2 mg) on pain and vital functions in patients undergoing total hip arthroplasty: a randomised controlled study.BMC Anesthesiol. 2022 Dec 5;22(1):377. doi: 10.1186/s12871-022-01919-8. BMC Anesthesiol. 2022. PMID: 36471258 Free PMC article. Clinical Trial.
-
Prescribing trend of tapentadol in a Sydney local health district.Br J Clin Pharmacol. 2022 Sep;88(9):3929-3935. doi: 10.1111/bcp.15448. Epub 2022 Jul 7. Br J Clin Pharmacol. 2022. PMID: 35763675 Free PMC article.
References
-
- Schwartz S, Etropolski MS, Shapiro DY, Rauschkolb C, Vinik AI, Lange B, et al. A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clin Drug Investig. 2015;35:95–108. https://doi.org/10.1007/s40261-014-0249-3 . - DOI - PubMed
-
- Tzschentke TM, Christoph T, Kogel B, Schiene K, Hennies HH, Englberger W et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323:265–76. - DOI
-
- Polati E, Canonico PL, Schweiger V, Collino M. Tapentadol: an overview of the safety profile. J Pain Res. 2019;12:1569–76. https://doi.org/10.2147/jpr.S190154 . - DOI - PubMed - PMC
-
- Wang X, Narayan SW, Penm J, Patanwala AE. Efficacy and Safety of Tapentadol Immediate Release for Acute Pain: A Systematic Review and Meta-analysis. Clin J Pain. 2020;36:399–409. https://doi.org/10.1097/AJP.0000000000000809 . - DOI - PubMed
-
- Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of postoperative pain: a clinical practice guideline from the american pain society, the american society of regional anesthesia and pain medicine, and the american society of anesthesiologists’ committee on regional anesthesia, executive committee, and administrative council. J Pain. 2016;17:131–57. https://doi.org/10.1016/j.jpain.2015.12.008 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources